Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

918.63 -17.37 (-1.86%)

Delayed Quote Updated: 1:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months ↗

September 26, 2026

There are good reasons behind analyst's bullish views of this biotech stock.

Via The Motley Fool

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. ↗

September 20, 2026

It's easy to be bullish about Argenx.

Via The Motley Fool

ARGENX SE - ADR (NASDAQ:ARGX) Meets Minervini Trend Template and High Growth Momentum ↗

September 17, 2026

Via Chartmill

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

September 04, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of...

Via Benzinga

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗

September 02, 2026

This biotech innovator could be in only the early chapters of its success story.

Via The Motley Fool

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story ↗

August 26, 2026

This biotech leader continues to rack up clinical successes.

Via The Motley Fool

Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 18, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC...

Via Benzinga

These Analysts Boost Their Forecasts On Argenx ↗

August 18, 2026

Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

August 17, 2026

Via Chartmill

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing ↗

August 17, 2026

argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients...

Via MarketBeat

Topics Intellectual Property

$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

August 17, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of...

Via Benzinga

Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

August 10, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of...

Via Benzinga

argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102 ↗

July 27, 2026

argenex (NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for...

Via MarketBeat

Topics Intellectual Property

argenex Q2 Earnings Call Highlights ↗

July 23, 2026

argenex (NASDAQ:ARGX) reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating...

Via MarketBeat

Topics Earnings Intellectual Property

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near ↗

June 12, 2026

Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic...

Via MarketBeat

Topics Intellectual Property Supply Chain

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗

June 05, 2026

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth,...

Via MarketBeat

Topics Intellectual Property

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Via MarketBeat

Topics ETFs Intellectual Property

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Topics Economy

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...

Via Stocktwits

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...

Via Finterra

Topics Earnings Economy Intellectual Property

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.